1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
2
|
Xu AM, Huang L, Liu W, Gao S, Han WX and
Wei ZJ: Neoadjuvant chemotherapy followed by surgery versus surgery
alone for gastric carcinoma: Systematic review and meta-analysis of
randomized controlled trials. PLoS One. 9:e869412014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN, 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
4
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
5
|
Song Z, Wu Y, Yang J, Yang D and Fang X:
Progress in the treatment of advanced gastric cancer. Tumour Biol.
39:10104283177146262017. View Article : Google Scholar : PubMed/NCBI
|
6
|
Memon MA, Subramanya MS, Khan S, Hossain
MB, Osland E and Memon B: Meta-analysis of D1 versus D2 gastrectomy
for gastric adenocarcinoma. Ann Surg. 253:900–911. 2011. View Article : Google Scholar : PubMed/NCBI
|
7
|
Xu AM, Huang L, Zhu L and Wei ZJ:
Significance of peripheral neutrophil-lymphocyte ratio among
gastric cancer patients and construction of a treatment-predictive
model: A study based on 1131 cases. Am J Cancer Res. 4:189–195.
2014.PubMed/NCBI
|
8
|
Huang L, Xu A, Li T, Han W, Wu S and Wang
Y: Detection of perioperative cancer antigen 72-4 in gastric juice
pre-and post-distal gastrectomy and its significances. Med Oncol.
30:6512013. View Article : Google Scholar : PubMed/NCBI
|
9
|
Ghosn M, Tabchi S, Kourie HR and Tehfe M:
Metastatic gastric cancer treatment: Second line and beyond. World
J Gastroenterol. 22:3069–3077. 2016. View Article : Google Scholar : PubMed/NCBI
|
10
|
Hammond SM: An overview of microRNAs. Adv
Drug Deliv Rev. 87:3–14. 2015. View Article : Google Scholar : PubMed/NCBI
|
11
|
Wilson RC and Doudna JA: Molecular
mechanisms of RNA interference. Annu Rev Biophys. 42:217–239. 2013.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
13
|
Miska EA: How microRNAs control cell
division, differentiation and death. Curr Opin Genet Dev.
15:563–568. 2010. View Article : Google Scholar
|
14
|
Ueda T, Volinia S, Okumura H, Shimizu M,
Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al:
Relation between microRNA expression and progression and prognosis
of gastric cancer: A microRNA expression analysis. Lancet Oncol.
11:136–146. 2010. View Article : Google Scholar : PubMed/NCBI
|
15
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Michael MZ, O'Connor SM, van Holst
Pellekaan NG, Young GP and James RJ: Reduced accumulation of
specific microRNAs in colorectal neoplasia. Mol Cancer Res.
1:882–891. 2003.PubMed/NCBI
|
17
|
Hu J, Guo H, Li H, Liu Y, Liu J, Chen L,
Zhang J and Zhang N: MiR-145 regulates epithelial to mesenchymal
transition of breast cancer cells by targeting Oct4. PLoS One.
7:e459652012. View Article : Google Scholar : PubMed/NCBI
|
18
|
Wang F, Xia J, Wang N and Zong H: miR-145
inhibits proliferation and invasion of esophageal squamous cell
carcinoma in part by targeting c-Myc. Onkologie. 36:754–758.
2013.PubMed/NCBI
|
19
|
Cho WC, Chow AS and Au JS: MiR-145
inhibits cell proliferation of human lung adenocarcinoma by
targeting EGFR and NUDT1. RNA Biol. 8:125–131. 2011. View Article : Google Scholar : PubMed/NCBI
|
20
|
Sachdeva M and Mo YY: MicroRNA-145
suppresses cell invasion and metastasis by directly targeting mucin
1. Cancer Res. 70:378–387. 2010. View Article : Google Scholar : PubMed/NCBI
|
21
|
Cui SY, Wang R and Chen LB: MicroRNA-145:
A potent tumour suppressor that regulates multiple cellular
pathways. J Cell Mol Med. 18:1913–1926. 2014. View Article : Google Scholar : PubMed/NCBI
|
22
|
Lei C, Du F, Sun L, Li T, Li T, Min Y, Nie
A, Wang X, Geng L, Lu Y, et al: miR-143 and miR-145 inhibit gastric
cancer cell migration and metastasis by suppressing MYO6. Cell
Death Dis. 8:e31012017. View Article : Google Scholar : PubMed/NCBI
|
23
|
Qiu T, Zhou X, Wang J, Du Y, Xu J, Huang
Z, Zhu W, Shu Y and Liu P: miR-145, miR-133A and miR-133b inhibit
proliferation, migration, invasion and cell cycle progression via
targeting transcription factor Sp1 in gastric cancer. FEBS Lett.
588:1168–1177. 2014. View Article : Google Scholar : PubMed/NCBI
|
24
|
Gao P, Xing AY, Zhou GY, Zhang TG, Zhang
JP, Gao C, Li H and Shi DB: The molecular mechanism of microRNA-145
to suppress invasion-metastasis cascade in gastric cancer.
Oncogene. 32:491–501. 2013. View Article : Google Scholar : PubMed/NCBI
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Guimarães RM and Muzi CD: Trend of
mortality rates for gastric cancer in Brazil and regions in the
period of 30 years (1980–2009). Arq Gastroenterol. 49:184–188.
2012. View Article : Google Scholar : PubMed/NCBI
|
27
|
Luo X, Burwinkel B, Tao S and Brenner H:
MicroRNA signatures: Novel biomarker for colorectal cancer? Cancer
Epidemiol Biomarkers Prev. 20:1272–1286. 2011. View Article : Google Scholar : PubMed/NCBI
|
28
|
Wang X, Tang S, Le SY, Lu R, Rader JS,
Meyers C and Zheng ZM: Aberrant expression of oncogenic and
tumor-suppressive microRNAs in cervical cancer is required for
cancer cell growth. PLoS One. 3:e25572008. View Article : Google Scholar : PubMed/NCBI
|
29
|
Iorio MV, Visone R, Di Leva G, Donati V,
Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et
al: MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
|
30
|
Liu X, Sempere LF, Galimberti F,
Freemantle SJ, Black C, Dragnev KH, Ma Y, Fiering S, Memoli V, Li
H, et al: Uncovering growth-suppressive MicroRNAs in lung cancer.
Clin Cancer Res. 15:1177–1183. 2009. View Article : Google Scholar : PubMed/NCBI
|
31
|
Hermeking H and Eick D: Mediation of
c-Myc-induced apoptosis by p53. Science. 265:2091–2093. 1994.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Maclean KH, Keller UB, Rodriguez-Galindo
C, Nilsson JA and Cleveland JL: c-Myc augments gamma
irradiation-induced apoptosis by suppressing Bcl-XL. Mol Cell Biol.
23:7256–7270. 2003. View Article : Google Scholar : PubMed/NCBI
|
33
|
Cannell IG, Kong YW, Johnston SJ, Chen ML,
Collins HM, Dobbyn HC, Elia A, Kress TR, Dickens M, Clemens MJ, et
al: p38 MAPK/MK2-mediated induction of miR-34c following DNA damage
prevents Myc-dependent DNA replication. Proc Natl Acad Sci USA.
107:5375–5380. 2010. View Article : Google Scholar : PubMed/NCBI
|
34
|
Shao Y, Qu Y, Dang S, Yao B and Ji M:
MiR-145 inhibits oral squamous cell carcinoma (OSCC) cell growth by
targeting c-Myc and Cdk6. Cancer Cell Int. 13:512013. View Article : Google Scholar : PubMed/NCBI
|
35
|
De Luca A, Maiello MR, D'Alessio A,
Pergameno M and Normanno N: The RAS/RAF/MEK/ERK and the PI3K/AKT
signalling pathways: Role in cancer pathogenesis and implications
for therapeutic approaches. Expert Opin Ther Targets. 16 (Suppl
2):S17–S27. 2012. View Article : Google Scholar : PubMed/NCBI
|
36
|
Aksamitiene E, Kiyatkin A and Kholodenko
BN: Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt
pathways: A fine balance. Biochem Soc Trans. 40:139–146. 2012.
View Article : Google Scholar : PubMed/NCBI
|
37
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: Regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|